Related Experiment Video
Updated: Jul 28, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.7K
Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer
1Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Abstract:
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival. See related article by Tolmeijer et al., p. 2835.
